FDA approves Mylan’s generic Advair
The U.S. Food and Drug Administration approved Mylan NV’s generic version of the GlaxoSmithKline-developed blockbuster asthma treatment Advair, driving shares of Mylan 7 percent higher.
Featured Posts
Pharma Innovators Special Feature 2018: Focus on innovation
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
2015 U.S. trends in aggregate spend, disclosure, and transparency
What are key trends in the transparency compliance landscape? And, how are life sciences manufacturers tackling growing requirements
J&J, U.S. states settle hip implant claims for $120 million
Johnson & Johnson and the company’s DePuy Orthopaedics unit have agreed to pay $120 million to resolve deceptive marketing claims by several U.S. states over the company’s metal-on-metal hip implants.
Abbott Offers a New Option for Physicians Treating Patients with Atrial Fibrillation
Abbott announced U.S. Food and Drug Administration approval of the TactiCath Contact Force Ablation Catheter, Sensor Enabled, a new ablation catheter designed to help physicians accurately and effectively treat atrial fibrillation (AFib).
Abbott To Acquire Cephea Valve Technologies
Abbott exercised an option to purchase Cephea Valve Technologies, a device company developing a less-invasive heart valve replacement technology for mitral valve disease.
Edward Lifesciences pays Boston Scientific $180 million to end patent row
Edwards Lifesciences Corp. paid rival Boston Scientific Corp. $180 million as part of a settlement to end long-standing patent disputes between the two medical device makers.
FDA Approves World’s First Device for Treatment of Premature Babies and Newborns with an Opening in Their Hearts
Abbott announced the U.S. Food and Drug Administration approved the Amplatzer Piccolo Occluder, the world’s first medical device that can be implanted in the tiniest babies using a minimally invasive procedure to treat patent ductus arteriosus (PDA).
Investing Into R&D Pays off for Some of Biotech’s Biggest Companies
PwC’s annual R&D spending report showcases companies that stand out in the field of biotechnology.
GeoVax and Enesi Pharma to Collaborate on Development of Multiple Vaccines
GeoVax Labs and Enesi Pharma announced a collaboration to develop solid-dose needle-free vaccine formulations utilizing GeoVax’s novel MVA-VLP vaccine platform in combination with Enesi’s ImplaVax device and formulation technology.
QurAlis Spins out Med Device Company EnClear to Target ALS
EnClear Therapies – a new medical device company spun out from QurAlis – will focus developmental programs on targeting neurological diseases, including amyotrophic lateral sclerosis and progressive supranuclear palsy.
Boston Scientific Exercises Option to Buy Millipede
Boston Scientific exercised the company’s option to buy the remaining shares of Santa Rosa, Calif.-based Millipede for $325 million.
Ad Right Top
MedAdNews
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.
February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!